Ravindranath Reddy, MD
Ophthalmology · Las Vegas, NVNPI 1578514253
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $18,600 of the $30,079 with a category attached, or 61.8%. Bausch & Lomb Americas Inc. accounts for 73.6% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $23,147, 7.7 times the $3,025 reported in 2019. Among ophthalmology clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 97 payments — averaging $310.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$22K
- Johnson & Johnson Surgical Vision, Inc.$2K
- Rxsight Inc$1K
- Alcon$1K
- Aerie Pharmaceuticals, Inc.$919
- AbbVie$411
- plus $2K from 9 others
What the payments were for
- Consulting fees$18,60062%
- Travel & lodging$4,43415%
- Food & beverage$7,04423%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 17 | $22,150 |
| Johnson & Johnson Surgical Vision, Inc. | 11 | $2,032 |
| Rxsight Inc | 11 | $1,271 |
| Alcon | 22 | $1,236 |
| Aerie Pharmaceuticals, Inc. | 4 | $919 |
| AbbVie | 5 | $411 |
| Tarsus Pharmaceuticals, Inc. | 9 | $364 |
| Sun Pharmaceutical Industries Inc. | 3 | $321 |
| Amgen(2 entities) | 5 | $315 |
| Oyster Point Pharma, Inc. | 3 | $262 |
| Novartis | 2 | $222 |
| Eyepoint US, Inc. | 2 | $178 |
| Eyevance Pharmaceuticals LLC | 1 | $148 |
| Sight Sciences, Inc. | 1 | $132 |
| Mallinckrodt Enterprises LLC | 1 | $118 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis Multifocal Family of 1-piece IOLS$1,489
- Tecnis Symfony IOL$1,489
- Tecnis 1-piece IOL$1,253
- RXSIGHT CONTACT LENS$966
- RXSIGHT INJECTOR CARTRIDGE$966
- RXSIGHT INJECTOR HANDPIECE$966
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$966
- Rocklatan$948
- LIGHT ADJUSTABLE LENS (LAL)$507
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$459
- Tecnis Simplicity$367
- Rhopressa$348
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$280
- TEPEZZA$257
- TYRVAYA$243
- XDEMVY$237
- TRYPTYR$229
- DEXYCU$163
- DURYSTA$149
- Zerviate$148
How this compares
$30,079 in reported general payments places this provider in the 90th percentile of 121 ophthalmology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 59 | $69,730 |
| XdemvyLotilaner | 13 | $24,331 |
| Cyclosporine | 13 | $8,656 |
| Prednisolone Acetate | 142 | $4,928 |
| Latanoprost | 338 | $4,099 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 340 | $3,804 |
| Flurbiprofen Sodium | 34 | $1,380 |
| Timolol Maleate | 125 | $957 |
| ErythromycinErythromycin Base | 84 | $937 |
| Azelastine Hcl | 12 | $521 |
| MoxifloxacinMoxifloxacin Hcl | 17 | $436 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 32 | $433 |
| Ofloxacin | 34 | $396 |
| Cromolyn Sodium | 26 | $362 |
| Doxycycline Monohydrate | 13 | $247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $411 | $69,73059 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $364 | $24,33113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 121 ophthalmology providers in Nevada.
Other ophthalmology in Las Vegas
- Eva LiangLas Vegas$496K
- Steven LeibowitzLas Vegas$147K
- Wonchon LinLas Vegas$43K
- Emily SchorrLas Vegas$17K
- Frank LeeLas Vegas$12K
- Tigran KostanyanLas Vegas$11K
- Tushina ReddyLas Vegas$11K
- Kent WellishLas Vegas$10K
- Eissa HannaLas Vegas$10K
- Surjeet SinghLas Vegas$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.